Nanogen (NGEN) Reports Q2 Loss of $0.07
Nanogen, Inc. (Nasdaq: NGEN) reports a Q2 loss of $0.07, compared to a $0.20 loss in the same quarter last year. Revenues for the quarter were $12.9 million, versus $10.7 million in Q207.
Nanogen, Inc., a diagnostics company, engages in developing, manufacturing, and selling diagnostic products for use in the in vitro diagnostic market in the United States, Canada, and Europe.
Nanogen, Inc., a diagnostics company, engages in developing, manufacturing, and selling diagnostic products for use in the in vitro diagnostic market in the United States, Canada, and Europe.
You May Also Be Interested In
- UPDATE: NetApp, Inc. (NTAP) Tops Q4 EPS by 3c; Guides Q1 Lower
- VeriFone Systems (PAY) Tops Q2 EPS by 3c; Guides Q3, FY12
- Flowers Foods, Inc. (FLO) Reports In-Line Q1 EPS; Adjusts FY12 EPS Growth Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
